Short answer
Astrana Health, Inc. (ASTH) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Q3 and nine-month 2026 financial results announced for periods ended September 30, 2026.
Astrana Health, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 and nine-month 2026 financial results announced for periods ended September 30, 2026
- Investors should review Exhibit 99.1 for revenue, profitability, cash flow and guidance details
Item 7.01 · Regulation FD Disclosure
- Conference call and webcast scheduled for November 5, 2026 at 2:30 p.m. Pacific Time
- Discussion covers financial results for the three and nine months ended September 30, 2026
- Earnings presentation available through Astrana Health’s investor relations website and Exhibit 99.2
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $1,023.6M, up 7%, with adjusted EBITDA $77.2M, up 13%, signaling operating leverage
- Net income attributable to Astrana $13.0M versus $0.4M, while adjusted EPS reached $0.71 versus $0.68
- Nine-month revenue $2,961.2M, up 33%, and adjusted EBITDA $212.4M, up 39%, strengthening full-year growth visibility
- Nine-month operating cash flow $117.1M and free cash flow $105.4M, supporting liquidity despite $115.9M of debt repayments
- 2026 guidance narrowed to revenue $3.9B-$4.0B, adjusted EBITDA $261M-$274M, and free cash flow $107.5M-$130M
Item EX-99.2 · Exhibit EX-99.2
- Q3 revenue $1,023.6M, up 7%, with capitation reaching $936.7M and signaling continued value-based care expansion
- Adjusted EBITDA $77.2M, up 13%, while margin improved to 8% from 7%, indicating operating leverage
- Net income attributable to Astrana $13.0M versus $0.4M, reflecting a sharp year-over-year earnings improvement
- FY2026 guidance narrowed to revenue $3,900-$4,000M and adjusted EBITDA $261-$274M, implying 24.1% and 30.2% midpoint growth
- Full-risk exposure expanding, with 82% of capitation revenue expected under full-risk arrangements and 43% of Care Partners members by year-end
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Astrana Health, Inc. 8-K filings
Get the next ASTH 8-K as it lands
Follow ASTH for push alerts, or ask the research agent what this filing means.